Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower plasma glucose concentration by inhibiting Na -glucose-coupled transport in the proximal tubule. Clinical trials demonstrate these drugs have favorable effects on cardiovascular outcomes to include slowing the progression...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical journal of the American Society of Nephrology Ročník 16; číslo 8; s. 1284
Hlavní autori: Palmer, Biff F, Clegg, Deborah J
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.08.2021
Predmet:
Blood Glucose - metabolism
Humans
Ketosis - blood
Ketosis - chemically induced
Ketosis - physiopathology
Ketosis - therapy
Kidney - drug effects
Kidney - physiopathology
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
euglycemic ketoacidosis
sodium glucose co-transporter inhibitor
ISSN:1555-905X, 1555-905X
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower plasma glucose concentration by inhibiting Na -glucose-coupled transport in the proximal tubule. Clinical trials demonstrate these drugs have favorable effects on cardiovascular outcomes to include slowing the progression of CKD. Although most patients tolerate these drugs, a potential complication is development of ketoacidosis, often with a normal or only a minimally elevated plasma glucose concentration. Inhibition of sodium-glucose cotransporter-2 in the proximal tubule alters kidney ATP turnover so that filtered ketoacids are preferentially excreted as Na or K salts, leading to indirect loss of bicarbonate from the body and systemic acidosis under conditions of increased ketogenesis. Risk factors include reductions in insulin dose, increased insulin demand, metabolic stress, low carbohydrate intake, women, and latent autoimmune diabetes of adulthood. The lack of hyperglycemia and nonspecific symptoms of ketoacidosis can lead to delays in diagnosis. Treatment strategies and various precautions are discussed that can decrease the likelihood of this complication.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1555-905X
1555-905X
DOI:10.2215/CJN.17621120